After-Hours Stock Movers:

Marqeta, Inc. (NASDAQ: MQ) 18.7% HIGHER; reported Q4 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $155.41 million versus the consensus estimate of $137.78 million.

Asana, Inc. (NYSE: ASAN) 17% LOWER; reported Q4 EPS of ($0.25), $0.03 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $111.9 million versus the consensus estimate of $105.16 million. Asana, Inc. sees Q1 2023 EPS of ($0.36)-($0.35), versus the consensus of ($0.27). Asana, Inc. sees Q1 2023 revenue of $114.5-115.5 million, versus the consensus of $110.91 million. Asana, Inc. sees FY2023 revenue of $527-531 million, versus the consensus of $506.3 million.

Fossil Group (NASDAQ: FOSL) 12.6% LOWER; reported Q4 EPS of $0.64, versus $0.19 reported last year. Revenue for the quarter came in at $604.3 million, versus $528.1 million reported last year.

CrowdStrike Holdings Inc. (NASDAQ: CRWD) 12.1% HIGHER; reported Q4 EPS of $0.30, $0.10 better than the analyst estimate of $0.20. Revenue for the quarter came in at $431 million versus the consensus estimate of $410.89 million. CrowdStrike Holdings Inc. sees Q1 2023 EPS of $0.22-$0.24, versus the consensus of $0.17. CrowdStrike Holdings Inc. sees Q1 2023 revenue of $458.9-465.4 million, versus the consensus of $440.8 million. CrowdStrike Holdings Inc. sees FY2023 EPS of $1.03-$1.13, versus the consensus of $0.91. CrowdStrike Holdings Inc. sees FY2023 revenue of $2.133-2.163 billion, versus the consensus of $2.01 billion.

Amazon.com, Inc. (NASDAQ: AMZN) 7% HIGHER; The Board of Directors approved a 20-for-1 split of the Company's common stock to be effected through an amendment to the Company's Restated Certificate of Incorporation. The Amendment will also effect a proportionate increase in the number of shares of authorized common stock. The Board of Directors also authorized the Company to repurchase up to $10 billion of the Company’s common stock.

Immutep Limited (NASDAQ: IMMP) 6.3% HIGHER; announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti or IMP321), in metastatic breast cancer (MBC).